Enliven initiated with a Buy at BTIG

BTIG initiated coverage of Enliven (ELVN) with a Buy rating and $42 price target Enliven is a precision oncology company developing targeted tyrosine kinase inhibitors directed against clinically validated targets BCR-ABL in CML, and HER2 in solid tumors, the analyst tells investors in a research note. The firm likes Enliven’s “rational” drug design strategy of leveraging differentiated chemistry against validated targets offering a potential solution to current unmet needs in “large lucrative markets.”